DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Provided By GlobeNewswire
Last update: Nov 12, 2025
Châtillon, France, November 11, 2025
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Read more at globenewswire.comNASDAQ:DBVT (12/10/2025, 2:22:04 PM)
19.64
+2.48 (+14.45%)
Find more stocks in the Stock Screener
DBVT Latest News and Analysis
